Company intelligence / Profile preview

Evaheart

Pittsburgh, Pennsylvania, United Statesevaheart-usa.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

The EVAHEART®2 Left Ventricular Assist Device has demonstrated over 9 years of durability testing with no mechanical failures. It has regulatory clearance and clinical use in Japan and ongoing pivotal clinical trials in the US under an FDA-approved IDE. Over 183 devices have been implanted as of July 2018. The system features a hydraulically levitated centrifugal pump and novel double cuff tipless inflow cannula designed to reduce complications such as stroke and clot formation.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically implantable mechanical circulatory support device)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

EVAHEART 2

Clinical Trial

Indications: Advanced heart failure

Partnerships

Sinovac led Series A investment round for China-based operations/Evaheart GmbH

Beyond the preview

Go deeper on Evaheart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evaheart.

Explore the full profile